Listed

Harvard Bioscience Inc

HBIONasdaqCIK 1123494TechnologyFiscal year ends Dec 31

Latest reported revenue, Q2 FY2026$22.7mRevenue, Q2 FY2026, three months to 2026-06-30$22.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-11, accession 0001171843-26-005425.Report this figureThree months to Jun 30, 2026, from the 10-Q filed Aug 11, 2026.

Latest quarter: Q2 FY2026

Three months to Jun 30, 2026, against the same quarter a year earlier.

  • Revenue$22.7mRevenue, Q2 FY2026, three months to 2026-06-30$22.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-11, accession 0001171843-26-005425.Report this figure+11.1% on a year earlier
  • Gross margin55.6%Gross margin, Q2 FY2026, three months to 2026-06-30. gross profit / revenueGross profit: $12.6m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-08-11, accession 0001171843-26-005425.Revenue: $22.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-11, accession 0001171843-26-005425.Report this figure−0.8 pts on a year earlier
  • Operating margin−4.3%Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: −$978.0k. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-11, accession 0001171843-26-005425.Revenue: $22.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-11, accession 0001171843-26-005425.Report this figure−0.3 pts on a year earlier
  • Net margin−12.8%Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: −$2.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-11, accession 0001171843-26-005425.Revenue: $22.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-11, accession 0001171843-26-005425.Report this figure−1.6 pts on a year earlier
  • Diluted EPS−$0.64Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.64 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-11, accession 0001171843-26-005425.Report this figure−23.1% on a year earlier
  • Free cash flow−$363.0kFree cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: $325.0k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-11, accession 0001171843-26-005425. Derived: 6-month figure less the 3-month figure.Capital expenditure: $688.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-11, accession 0001171843-26-005425. Derived: 6-month figure less the 3-month figure.Report this figureSign changed from a year earlier

Last eight quarters

Full statements
Revenue$22.7mGross margin 55.6%
Diluted EPS−$0.64, Q2 FY2026
Free cash flow−$363.0k, Q2 FY2026
Harvard Bioscience Inc, key figures for the last eight quarters
Line itemUnitQ3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30Shape over the periods
Revenue$m22.0Revenue, Q3 FY2024, three months to 2024-09-30$22.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-06, accession 0001171843-25-007099.Report this figure24.6Revenue, Q4 FY2024, three months to 2024-12-31$24.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-13, accession 0001171843-26-001548. Derived: 12-month figure less the 9-month figure.Report this figure21.8Revenue, Q1 FY2025, three months to 2025-03-31$21.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-12, accession 0001171843-26-003311.Report this figure20.5Revenue, Q2 FY2025, three months to 2025-06-30$20.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-11, accession 0001171843-26-005425.Report this figure20.6Revenue, Q3 FY2025, three months to 2025-09-30$20.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-06, accession 0001171843-25-007099.Report this figure23.7Revenue, Q4 FY2025, three months to 2025-12-31$23.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-13, accession 0001171843-26-001548. Derived: 12-month figure less the 9-month figure.Report this figure20.8Revenue, Q1 FY2026, three months to 2026-03-31$20.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-12, accession 0001171843-26-003311.Report this figure22.7Revenue, Q2 FY2026, three months to 2026-06-30$22.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-11, accession 0001171843-26-005425.Report this figure
Gross margin%58.1%Gross margin, Q3 FY2024, three months to 2024-09-30. gross profit / revenueGross profit: $12.8m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2025-11-06, accession 0001171843-25-007099.Revenue: $22.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-06, accession 0001171843-25-007099.Report this figure57.1%Gross margin, Q4 FY2024, three months to 2024-12-31. gross profit / revenueGross profit: $14.0m. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-03-13, accession 0001171843-26-001548. Derived: 12-month figure less the 9-month figure.Revenue: $24.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-13, accession 0001171843-26-001548. Derived: 12-month figure less the 9-month figure.Report this figure56.0%Gross margin, Q1 FY2025, three months to 2025-03-31. gross profit / revenueGross profit: $12.2m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-05-12, accession 0001171843-26-003311.Revenue: $21.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-12, accession 0001171843-26-003311.Report this figure56.4%Gross margin, Q2 FY2025, three months to 2025-06-30. gross profit / revenueGross profit: $11.5m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-08-11, accession 0001171843-26-005425.Revenue: $20.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-11, accession 0001171843-26-005425.Report this figure58.4%Gross margin, Q3 FY2025, three months to 2025-09-30. gross profit / revenueGross profit: $12.0m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2025-11-06, accession 0001171843-25-007099.Revenue: $20.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-06, accession 0001171843-25-007099.Report this figure59.7%Gross margin, Q4 FY2025, three months to 2025-12-31. gross profit / revenueGross profit: $14.2m. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-03-13, accession 0001171843-26-001548. Derived: 12-month figure less the 9-month figure.Revenue: $23.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-13, accession 0001171843-26-001548. Derived: 12-month figure less the 9-month figure.Report this figure59.0%Gross margin, Q1 FY2026, three months to 2026-03-31. gross profit / revenueGross profit: $12.2m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-05-12, accession 0001171843-26-003311.Revenue: $20.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-12, accession 0001171843-26-003311.Report this figure55.6%Gross margin, Q2 FY2026, three months to 2026-06-30. gross profit / revenueGross profit: $12.6m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-08-11, accession 0001171843-26-005425.Revenue: $22.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-11, accession 0001171843-26-005425.Report this figure
Operating margin%(8.5%)Operating margin, Q3 FY2024, three months to 2024-09-30. operating income / revenueOperating income: −$1.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-06, accession 0001171843-25-007099.Revenue: $22.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-06, accession 0001171843-25-007099.Report this figure0.0%Operating margin, Q4 FY2024, three months to 2024-12-31. operating income / revenueOperating income: $11.0k. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-13, accession 0001171843-26-001548. Derived: 12-month figure less the 9-month figure.Revenue: $24.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-13, accession 0001171843-26-001548. Derived: 12-month figure less the 9-month figure.Report this figure(228.1%)Operating margin, Q1 FY2025, three months to 2025-03-31. operating income / revenueOperating income: −$49.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-12, accession 0001171843-26-003311.Revenue: $21.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-12, accession 0001171843-26-003311.Report this figure(4.0%)Operating margin, Q2 FY2025, three months to 2025-06-30. operating income / revenueOperating income: −$819.0k. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-11, accession 0001171843-26-005425.Revenue: $20.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-11, accession 0001171843-26-005425.Report this figure1.0%Operating margin, Q3 FY2025, three months to 2025-09-30. operating income / revenueOperating income: $197.0k. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-06, accession 0001171843-25-007099.Revenue: $20.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-06, accession 0001171843-25-007099.Report this figure7.2%Operating margin, Q4 FY2025, three months to 2025-12-31. operating income / revenueOperating income: $1.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-13, accession 0001171843-26-001548. Derived: 12-month figure less the 9-month figure.Revenue: $23.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-13, accession 0001171843-26-001548. Derived: 12-month figure less the 9-month figure.Report this figure(5.7%)Operating margin, Q1 FY2026, three months to 2026-03-31. operating income / revenueOperating income: −$1.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-12, accession 0001171843-26-003311.Revenue: $20.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-12, accession 0001171843-26-003311.Report this figure(4.3%)Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: −$978.0k. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-11, accession 0001171843-26-005425.Revenue: $22.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-11, accession 0001171843-26-005425.Report this figure
Net margin%(21.9%)Net margin, Q3 FY2024, three months to 2024-09-30. net income / revenueNet income: −$4.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001171843-25-007099.Revenue: $22.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-06, accession 0001171843-25-007099.Report this figure0.1%Net margin, Q4 FY2024, three months to 2024-12-31. net income / revenueNet income: $18.0k. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-13, accession 0001171843-26-001548. Derived: 12-month figure less the 9-month figure.Revenue: $24.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-13, accession 0001171843-26-001548. Derived: 12-month figure less the 9-month figure.Report this figure(231.2%)Net margin, Q1 FY2025, three months to 2025-03-31. net income / revenueNet income: −$50.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-12, accession 0001171843-26-003311.Revenue: $21.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-12, accession 0001171843-26-003311.Report this figure(11.2%)Net margin, Q2 FY2025, three months to 2025-06-30. net income / revenueNet income: −$2.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-11, accession 0001171843-26-005425.Revenue: $20.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-11, accession 0001171843-26-005425.Report this figure(6.0%)Net margin, Q3 FY2025, three months to 2025-09-30. net income / revenueNet income: −$1.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001171843-25-007099.Revenue: $20.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-06, accession 0001171843-25-007099.Report this figure(12.0%)Net margin, Q4 FY2025, three months to 2025-12-31. net income / revenueNet income: −$2.8m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-13, accession 0001171843-26-001548. Derived: 12-month figure less the 9-month figure.Revenue: $23.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-13, accession 0001171843-26-001548. Derived: 12-month figure less the 9-month figure.Report this figure(16.5%)Net margin, Q1 FY2026, three months to 2026-03-31. net income / revenueNet income: −$3.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-12, accession 0001171843-26-003311.Revenue: $20.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-12, accession 0001171843-26-003311.Report this figure(12.8%)Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: −$2.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-11, accession 0001171843-26-005425.Revenue: $22.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-11, accession 0001171843-26-005425.Report this figure
Diluted EPS$ per share(0.11)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$0.11 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-06, accession 0001171843-25-007099.Report this figurenot reported (Diluted EPS not reported)(11.42)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$11.42 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-12, accession 0001171843-26-003311.Report this figure(0.52)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.52 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-11, accession 0001171843-26-005425.Report this figure(0.03)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.03 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-06, accession 0001171843-25-007099.Report this figurenot reported (Diluted EPS not reported)(0.77)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.77 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-12, accession 0001171843-26-003311.Report this figure(0.64)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.64 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-11, accession 0001171843-26-005425.Report this figure
Free cash flow$m(1.7)Free cash flow, Q3 FY2024, three months to 2024-09-30. operating cash flow − capital expenditureOperating cash flow: −$842.0k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-06, accession 0001171843-25-007099. Derived: 9-month figure less the 6-month figure.Capital expenditure: $880.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-06, accession 0001171843-25-007099. Derived: 9-month figure less the 6-month figure.Report this figure1.4Free cash flow, Q4 FY2024, three months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: $1.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-13, accession 0001171843-26-001548. Derived: 12-month figure less the 9-month figure.Capital expenditure: $301.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-13, accession 0001171843-26-001548. Derived: 12-month figure less the 9-month figure.Report this figure2.5Free cash flow, Q1 FY2025, three months to 2025-03-31. operating cash flow − capital expenditureOperating cash flow: $3.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-12, accession 0001171843-26-003311.Capital expenditure: $513.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-12, accession 0001171843-26-003311.Report this figure2.7Free cash flow, Q2 FY2025, three months to 2025-06-30. operating cash flow − capital expenditureOperating cash flow: $2.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-11, accession 0001171843-26-005425. Derived: 6-month figure less the 3-month figure.Capital expenditure: $89.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-11, accession 0001171843-26-005425. Derived: 6-month figure less the 3-month figure.Report this figure0.9Free cash flow, Q3 FY2025, three months to 2025-09-30. operating cash flow − capital expenditureOperating cash flow: $1.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-06, accession 0001171843-25-007099. Derived: 9-month figure less the 6-month figure.Capital expenditure: $207.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-06, accession 0001171843-25-007099. Derived: 9-month figure less the 6-month figure.Report this figure(0.5)Free cash flow, Q4 FY2025, three months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: −$96.0k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-13, accession 0001171843-26-001548. Derived: 12-month figure less the 9-month figure.Capital expenditure: $449.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-13, accession 0001171843-26-001548. Derived: 12-month figure less the 9-month figure.Report this figure(1.1)Free cash flow, Q1 FY2026, three months to 2026-03-31. operating cash flow − capital expenditureOperating cash flow: −$662.0k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-12, accession 0001171843-26-003311.Capital expenditure: $426.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-12, accession 0001171843-26-003311.Report this figure(0.4)Free cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: $325.0k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-11, accession 0001171843-26-005425. Derived: 6-month figure less the 3-month figure.Capital expenditure: $688.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-11, accession 0001171843-26-005425. Derived: 6-month figure less the 3-month figure.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Last five fiscal years

Revenue$86.5mGross margin 57.7%
Diluted EPS−$1.28, FY2025
Free cash flow$5.5m, FY2025
Harvard Bioscience Inc, key figures for the last five fiscal years
Line itemUnitFY20212021-12-31FY20222022-12-31FY20232023-12-31FY20242024-12-31FY20252025-12-31Shape over the periods
Revenue$m119Revenue, FY2021, twelve months to 2021-12-31$118.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2023-03-09, accession 0001171843-23-001566.Report this figure113Revenue, FY2022, twelve months to 2022-12-31$113.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-03-07, accession 0001171843-24-001239.Report this figure112Revenue, FY2023, twelve months to 2023-12-31$112.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-14, accession 0001171843-25-001472.Report this figure94.1Revenue, FY2024, twelve months to 2024-12-31$94.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-13, accession 0001171843-26-001548.Report this figure86.6Revenue, FY2025, twelve months to 2025-12-31$86.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-13, accession 0001171843-26-001548.Report this figure
Gross margin%56.9%Gross margin, FY2021, twelve months to 2021-12-31. gross profit / revenueGross profit: $67.7m. XBRL concept us-gaap:GrossProfit. 10-K filed 2023-03-09, accession 0001171843-23-001566.Revenue: $118.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2023-03-09, accession 0001171843-23-001566.Report this figure53.7%Gross margin, FY2022, twelve months to 2022-12-31. gross profit / revenueGross profit: $60.8m. XBRL concept us-gaap:GrossProfit. 10-K filed 2024-03-07, accession 0001171843-24-001239.Revenue: $113.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-03-07, accession 0001171843-24-001239.Report this figure58.9%Gross margin, FY2023, twelve months to 2023-12-31. gross profit / revenueGross profit: $66.1m. XBRL concept us-gaap:GrossProfit. 10-K filed 2025-03-14, accession 0001171843-25-001472.Revenue: $112.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-14, accession 0001171843-25-001472.Report this figure58.2%Gross margin, FY2024, twelve months to 2024-12-31. gross profit / revenueGross profit: $54.8m. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-03-13, accession 0001171843-26-001548.Revenue: $94.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-13, accession 0001171843-26-001548.Report this figure57.7%Gross margin, FY2025, twelve months to 2025-12-31. gross profit / revenueGross profit: $49.9m. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-03-13, accession 0001171843-26-001548.Revenue: $86.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-13, accession 0001171843-26-001548.Report this figure
Operating margin%1.7%Operating margin, FY2021, twelve months to 2021-12-31. operating income / revenueOperating income: $2.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2023-03-09, accession 0001171843-23-001566.Revenue: $118.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2023-03-09, accession 0001171843-23-001566.Report this figure(6.1%)Operating margin, FY2022, twelve months to 2022-12-31. operating income / revenueOperating income: −$6.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2024-03-07, accession 0001171843-24-001239.Revenue: $113.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-03-07, accession 0001171843-24-001239.Report this figure1.7%Operating margin, FY2023, twelve months to 2023-12-31. operating income / revenueOperating income: $1.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-03-14, accession 0001171843-25-001472.Revenue: $112.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-14, accession 0001171843-25-001472.Report this figure(6.6%)Operating margin, FY2024, twelve months to 2024-12-31. operating income / revenueOperating income: −$6.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-13, accession 0001171843-26-001548.Revenue: $94.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-13, accession 0001171843-26-001548.Report this figure(56.1%)Operating margin, FY2025, twelve months to 2025-12-31. operating income / revenueOperating income: −$48.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-13, accession 0001171843-26-001548.Revenue: $86.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-13, accession 0001171843-26-001548.Report this figure
Net margin%(0.2%)Net margin, FY2021, twelve months to 2021-12-31. net income / revenueNet income: −$288.0k. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2023-03-09, accession 0001171843-23-001566.Revenue: $118.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2023-03-09, accession 0001171843-23-001566.Report this figure(8.4%)Net margin, FY2022, twelve months to 2022-12-31. net income / revenueNet income: −$9.5m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2024-03-07, accession 0001171843-24-001239.Revenue: $113.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-03-07, accession 0001171843-24-001239.Report this figure(3.0%)Net margin, FY2023, twelve months to 2023-12-31. net income / revenueNet income: −$3.4m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-03-14, accession 0001171843-25-001472.Revenue: $112.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-14, accession 0001171843-25-001472.Report this figure(13.2%)Net margin, FY2024, twelve months to 2024-12-31. net income / revenueNet income: −$12.4m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-13, accession 0001171843-26-001548.Revenue: $94.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-13, accession 0001171843-26-001548.Report this figure(65.5%)Net margin, FY2025, twelve months to 2025-12-31. net income / revenueNet income: −$56.7m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-13, accession 0001171843-26-001548.Revenue: $86.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-13, accession 0001171843-26-001548.Report this figure
Diluted EPS$ per share(0.01)Diluted EPS, FY2021, twelve months to 2021-12-31−$0.01 per share. XBRL concept us-gaap:EarningsPerShareBasicAndDiluted. 10-K filed 2022-03-11, accession 0001171843-22-001806.Report this figure(0.23)Diluted EPS, FY2022, twelve months to 2022-12-31−$0.23 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2024-03-07, accession 0001171843-24-001239.Report this figure(0.08)Diluted EPS, FY2023, twelve months to 2023-12-31−$0.08 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2025-03-14, accession 0001171843-25-001472.Report this figure(0.28)Diluted EPS, FY2024, twelve months to 2024-12-31−$0.28 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-03-13, accession 0001171843-26-001548.Report this figure(1.28)Diluted EPS, FY2025, twelve months to 2025-12-31−$1.28 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-03-13, accession 0001171843-26-001548.Report this figure
Free cash flow$m0.1Free cash flow, FY2021, twelve months to 2021-12-31. operating cash flow − capital expenditureOperating cash flow: $1.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2023-03-09, accession 0001171843-23-001566.Capital expenditure: $1.2m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2023-03-09, accession 0001171843-23-001566.Report this figure(0.4)Free cash flow, FY2022, twelve months to 2022-12-31. operating cash flow − capital expenditureOperating cash flow: $1.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2024-03-07, accession 0001171843-24-001239.Capital expenditure: $1.6m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2024-03-07, accession 0001171843-24-001239.Report this figure12.2Free cash flow, FY2023, twelve months to 2023-12-31. operating cash flow − capital expenditureOperating cash flow: $14.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-03-14, accession 0001171843-25-001472.Capital expenditure: $1.8m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-03-14, accession 0001171843-25-001472.Report this figure(1.2)Free cash flow, FY2024, twelve months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: $1.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-13, accession 0001171843-26-001548.Capital expenditure: $2.6m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-13, accession 0001171843-26-001548.Report this figure5.5Free cash flow, FY2025, twelve months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: $6.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-13, accession 0001171843-26-001548.Capital expenditure: $1.3m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-13, accession 0001171843-26-001548.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Insider purchases and sales

All insider transactions

The last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.

No open-market purchases or sales by insiders are in coverage from Nov 2024 to Oct 2026.

No open-market purchases or sales by insiders are in coverage for this company.

Funds that report holding it

All funds

From each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.

Funds that report holding Harvard Bioscience Inc
FundQuarter endedReported valueSharesPut or callChange on the quarter before
WEBER CAPITAL MANAGEMENT LLC /ADV2026-06-30$1.9m310,861Reduced−9,176
VANGUARD CAPITAL MANAGEMENT LLC2026-06-30$1.0m169,625Added+6,312
CORSAIR CAPITAL MANAGEMENT, L.P.2026-06-30$755.3k122,810Reduced−2,000
TWO SIGMA INVESTMENTS, LP2026-06-30$704.5k114,545Added+428
RENAISSANCE TECHNOLOGIES LLC2026-06-30$610.9k99,327Reduced−2,100
BlackRock, Inc.2026-06-30$380.3k61,834Reduced−392
GEODE CAPITAL MANAGEMENT, LLC2026-06-30$292.5k47,555Reduced−11,956
Mink Brook Asset Management LLC2026-06-30$205.2k33,369New+33,369
MILLENNIUM MANAGEMENT LLC2026-06-30$200.6k32,620Reduced−13,712
VANGUARD FIDUCIARY TRUST CO2026-06-30$170.5k27,730Unchanged

Recent filings

All 940 filings

Reports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.

Harvard Bioscience Inc, recent filings
FiledFormWhat it isAccession number
2026-08-1116:30 ET10-QQuarterly reportPeriod 2026-06-300001171843-26-005425
2026-08-1107:00 ET8-K7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001171843-26-005406
2026-08-1107:00 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001171843-26-005405
2026-06-0216:01 ET8-K5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits0001171843-26-003877
2026-05-1216:30 ET10-QQuarterly reportPeriod 2026-03-310001171843-26-003311
2026-05-1207:30 ET8-K7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001171843-26-003271
2026-05-1207:30 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001171843-26-003270
2026-04-2116:56 ETDEF 14AProxy statementPeriod 2026-06-020001171843-26-002617
2026-03-2308:00 ETSCHEDULE 13DOwnership report, active investor0001171843-26-001839
2026-03-1707:30 ET8-K7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001171843-26-001614

Latest annual report

Form 10-K for the fiscal year ended Dec 31, 2025Filed Mar 13, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.

Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by [object Promise].Forecast this quarter

About the filer

CIK
1123494
Tickers
HBIO
Exchange
Nasdaq
SIC code
3826 Laboratory Analytical Instruments
Sector
Technology
Fiscal year ends
Dec 31
Incorporated in
DE
Filer category
Non-accelerated filer<br>Smaller reporting company

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:34 ET. Listed shows no prices and gives no investment advice.